Fidelity Investments’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,548,000
| Closed | -$278M | – | 2770 |
|
|
2017
Q3 | $278M | Buy |
1,548,000
+1,412,702
| +1,044% | +$197M | 0.03% | 553 |
|
|
2017
Q2 | $14M | Sell |
135,298
-712,075
| -84% | -$58.1M | ﹤0.01% | 1817 |
|
|
2017
Q1 | $66.5M | Sell |
847,373
-56,200
| -6% | -$3.48M | 0.01% | 1168 |
|
|
2016
Q4 | $40.5M | Sell |
903,573
-358,600
| -28% | -$17.6M | 0.01% | 1394 |
|
|
2016
Q3 | $70.5M | Sell |
1,262,173
-1,053,755
| -46% | -$58.7M | 0.01% | 1148 |
|
|
2016
Q2 | $116M | Sell |
2,315,928
-395,700
| -15% | -$19.4M | 0.02% | 910 |
|
|
2016
Q1 | $124M | Sell |
2,711,628
-833,000
| -24% | -$40.3M | 0.02% | 876 |
|
|
2015
Q4 | $218M | Buy |
3,544,628
+372,225
| +12% | +$26.2M | 0.03% | 622 |
|
|
2015
Q3 | $177M | Sell |
3,172,403
-79,600
| -2% | -$5.01M | 0.03% | 690 |
|
|
2015
Q2 | $198M | Buy |
3,252,003
+426,061
| +15% | +$24.3M | 0.03% | 697 |
|
|
2015
Q1 | $163M | Buy |
2,825,942
+857,848
| +44% | +$57.5M | 0.02% | 786 |
|
|
2014
Q4 | $114M | Buy |
1,968,094
+976,339
| +98% | +$41.1M | 0.01% | 948 |
|
|
2014
Q3 | $28.3M | Buy |
+991,755
| New | +$24.5M | ﹤0.01% | 1583 |
|
Fidelity Investments's KITE Position: Q4 2017 in Review
Fidelity Investments sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 1,548,000 shares — an estimated $278M sold.
Fidelity Investments first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $278M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Fidelity Investments reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Fidelity Investments sold 1,548,000 Kite Pharma, Inc. shares in Q4 2017, an estimated $278M.
- Fidelity Investments first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Fidelity Investments's Kite Pharma, Inc. position peaked at $278M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Fidelity Investments's 13F filing for Q4 2017, filed 12 Feb 2018.